Drugs / SYN608
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07088588 | Jul 2025 → Jul 2028 expected | breast cancer, metastatic neoplasm, ovarian cancer | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYN608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07088588 ↗ |
| Action | Inhibit | “a Poly ADP-ribose Glycohydrolase (PARG) Inhibitor” NCT07088588 ↗ |
| Route | Oral | “administered orally” NCT07088588 ↗ |
| Target | PARG | “a Poly ADP-ribose Glycohydrolase (PARG) Inhibitor” NCT07088588 ↗ |